Growing 26.1% across the seven major pharmaceutical markets to reach $8.02 billion in 2003, the anticonvulsant market is one of the largest and most lucrative CNS areas. Growth is driven primarily by uptake of newer drugs for a plethora of indications.

Key findings indicate that pharmaceutical promotional campaigns have to be aligned with physicians` exact information requirements if engagement and persuasion is to be increased. Consequently, the factors that feed into the decisions prescribers make

Use this report’s 28 commercial variables to build your own, customized data sets for cancer drug launches.

Build a business development function that wins key deals. This report features qualitative and quantitative findings from 22 different companies that range from the industry’s top ten to up-and-coming biotechs.

The report is an invaluable resource illustrating how not only the medical device manufacturers manage their brand strategy to garner positive competitive advantage.

The report is comprised of ten stand-alone articles which reflect a range of personal perspectives on the leading issues surrounding pharmaceutical brand management, both now and in the future.

This report outlines key generics players and the strategies they are using to capture a larger market share of the drugs market.

Every pharmaceutical company, from industry leaders to start-up biotechnology firms, is involved in building, developing and benefiting from thought leader relationships.

Developing lifecycle management strategies to maximize branded drugs’ profitability is a key strategy for the pharmaceutical industry.